Physician profile
Maureen E Bruns
NPI 1457397622
$2,911.63
in general payments reported to CMS, 2019-2025
24 companies · $51.75 in 2025
The $51.75 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $1,145 · 2023: $718 · 2024: $99.80 · 2025: $51.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $668.65 | 2021-2023 | Relistor |
| Boston Scientific Corporation | $524.94 | 2021-2025 | General - Pain Management |
| Abbott Laboratories | $508.12 | 2022 | |
| Abbvie INC. | $269.17 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $228.86 | 2021-2023 | Belbuca, Xtampza |
| Teva Pharmaceuticals USA, INC. | $69.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $65.13 | 2021 | |
| Pfizer INC. | $63.03 | 2021-2023 | |
| Lilly USA, LLC | $59.53 | 2021 | |
| Upsher-Smith Laboratories LLC | $57.29 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.76 | 2022 | |
| Virtus Pharmaceuticals LLC | $43.48 | 2021 | |
| Spr Therapeutics, INC | $42.16 | 2022 | |
| Grt US Holding, INC. | $41.04 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $35.26 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $31.34 | 2022 | |
| Biodelivery Sciences International, INC. | $29.01 | 2021 | |
| Averitas Pharma INC. | $22.97 | 2023 | Qutenza |
| Medtronic, INC. | $22.39 | 2021 | |
| International Rehabilitative Sciences, INC | $19.87 | 2023 | Rs 4i Plus Sequential Stimulator |
| Axonics, INC. | $16.12 | 2022 | |
| Si-Bone, INC. | $14.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.02 | 2021 | |
| Ibsa Pharma INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Bruns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.